PHILADELPHIA — Alcohol is the leading known preventable cause of developmental and physical birth defects in the United States, according to Kidshealth.org, but despite that, many women still drink during pregnancy. About 1 in every 750 infants is born with fetal alcohol syndrome and another 40,000 with fetal alcohol effects.
To help identify damage to the fetus earlier so that better intervention is possible, a research team at Temple University School of Medicine is developing a test to identify maternal blood biomarkers that can assess fetal neurodevelopment in the first and second trimesters.
This project was a recent winner of Bill & Melinda Gates Foundation’s Grand Challenges Explorations grants. Temple was one 60 winners who will focus on solving persistent global health and development challenges.
Dr. Laura Goetzl, a professor of obstetrics, gynecology and reproductive sciences, and her research team will be working with the Shriners Hospitals Center for Neural Repair and Rehabilitation to develop a noninvasive maternal blood test that will help predict abnormal fetal neurodevelopment. Specifically they will be focusing on the effects of antidepressants, amphetamines and alcohol.